Dr. Reddy's Laboratories Switzerland Acquires Haleon Group's Nicotine Replacement Therapy Brands Outside US for GBP 458M, Plus Up to GBP 42M in Contingent Payments in CY 2025 and CY 2026
Portfolio Pulse from Benzinga Newsdesk
Dr. Reddy's Laboratories Switzerland has acquired Haleon Group's nicotine replacement therapy brands outside the US for GBP 458 million, with an additional contingent payment of up to GBP 42 million in 2025 and 2026.
June 26, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Dr. Reddy's Laboratories Switzerland has acquired Haleon Group's nicotine replacement therapy brands outside the US for GBP 458 million, with an additional contingent payment of up to GBP 42 million in 2025 and 2026.
The acquisition expands Dr. Reddy's product portfolio in the nicotine replacement therapy market outside the US, potentially increasing revenue and market share. The contingent payments indicate confidence in future performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100